Over-the-Counter Drug Cuts Colorectal Cancer Recurrence by Half

New Study Reveals Aspirin’s Potential in Reducing Colorectal Cancer Recurrence

A recent study has uncovered a promising development in the fight against colorectal cancer. Researchers have found that a low dose of aspirin could significantly reduce the risk of cancer returning in patients with a specific genetic mutation. This discovery highlights the potential of a widely available and affordable medication to make a meaningful impact on cancer treatment.

The research, conducted by scientists at Karolinska Institutet and Karolinska University Hospital, involved more than 3,500 patients from Sweden, Norway, Denmark, and Finland who had undergone surgery to remove their tumors. The participants were divided into two groups, with one receiving 160 milligrams of aspirin daily and the other a placebo. After three years, the results showed a 55% reduction in cancer recurrence among those taking aspirin compared to the placebo group.

This finding is particularly significant for patients whose tumors carry a mutation in the PIK3 signaling pathway. According to Dr. Anna Martling, a professor at Karolinska Institutet and senior consultant surgeon at Karolinska University Hospital, this mutation affects more than one-third of all colorectal cancer patients. She emphasized that the ALASCCA trial marks the first time that low-dose aspirin has been shown to reduce recurrence in a randomized setting.

Martling noted that the effect was stronger in women, although further research is needed to understand why. The study was published in the New England Journal of Medicine, underscoring its credibility and importance within the medical community.

Aspirin, a common over-the-counter medication, is known for its ability to relieve pain, fever, and inflammation. It is also used in low doses to prevent blood clots. Compared to many modern cancer drugs, aspirin is inexpensive and accessible globally, making it a potentially valuable tool in cancer care.

Dr. Marc Siegel, a senior medical analyst at Fox News, commented on the findings, noting that prior observational studies have suggested similar benefits of aspirin in reducing colon cancer risk. He highlighted that the PIK3CA mutation, which is present in about 30% of colon cancers, leads to rapid cell growth. Siegel reiterated that the Scandinavian study showed a greater than 50% reduction in recurrence among patients with this mutation.

Despite the promising results, the researchers acknowledged some limitations. The study was not powered for detailed subgroup analyses, and patients over the age of 80 were not included. Additionally, longer follow-up is needed to confirm the effects on overall survival.

Common side effects of aspirin include stomach problems and an increased risk of bleeding. It should not be used by individuals with stomach ulcers, bleeding disorders, or asthma. Those taking other blood-thinning agents or consuming alcohol should use aspirin with caution, as advised by experts.

Martling emphasized that the findings are immediately relevant for clinicians and guideline committees. She recommended that testing for PI3K pathway alterations should be considered for colorectal cancer patients after surgery. However, she cautioned that aspirin should not be used outside of a medical context until guidelines and treating physicians adopt these findings.

The study represents a strong example of precision medicine, where high-technology platforms meet a well-known, low-cost drug. Martling added that if broadly implemented, this regimen could prevent thousands of recurrences and save lives each year, especially in areas with limited access to expensive novel drugs.

While the results are encouraging, Dr. Siegel stressed the importance of analyzing the risks and benefits of aspirin use on a case-by-case basis. He believes that aspirin should be more commonly used for this purpose than previously, but careful consideration is necessary.

The study was funded in part by the Swedish Research Council and the Swedish Cancer Society, highlighting the support for innovative research in cancer treatment. As the medical community continues to explore the potential of aspirin in reducing cancer recurrence, this study offers hope for a more accessible and effective approach to managing colorectal cancer.